Tissue penetration of antimicrobials: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
Line 10: | Line 10: | ||
! colspan="7" |Antibiotics: β-Lactams |
! colspan="7" |Antibiotics: β-Lactams |
||
|- |
|- |
||
| rowspan=" |
| rowspan="3" |Penicillins |
||
|β-lactamase inhibitors |
|β-lactamase inhibitors |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| |
| |
||
| |
| |
||
Line 23: | Line 23: | ||
| |
| |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
|- |
|- |
||
|[[piperacillin-tazobactam]] |
|||
⚫ | |||
| |
|||
| |
|||
| |
|||
| +† |
|||
| |
|||
|- |
|||
⚫ | |||
|first-generation cephalosporins |
|first-generation cephalosporins |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| |
| |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
|- |
|- |
||
|second-generation cephalosporins |
|second-generation cephalosporins |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| |
|||
| |
|||
| |
|||
|- |
|||
|third-generation cephalosporins |
|||
| |
|||
| |
| |
||
| |
| |
||
| +† |
|||
| |
| |
||
|- |
|- |
||
Line 57: | Line 71: | ||
|[[cephamycins]] |
|[[cephamycins]] |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| |
| |
||
| |
| |
||
Line 67: | Line 81: | ||
| |
| |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
|- |
|- |
||
|Carbapenems |
|Carbapenems |
||
Line 85: | Line 99: | ||
| |
| |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
|- |
|- |
||
|Chloramphenicol |
|Chloramphenicol |
||
Line 98: | Line 112: | ||
| |
| |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |–? |
||
| |
| |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 106: | Line 120: | ||
|[[clindamycin]] |
|[[clindamycin]] |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| |
| |
||
| |
| |
||
Line 114: | Line 128: | ||
|[[macrolides]] |
|[[macrolides]] |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| |
| |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 121: | Line 135: | ||
|Nitrofurans |
|Nitrofurans |
||
|[[nitrofurantoin]] |
|[[nitrofurantoin]] |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
|- |
|- |
||
|Nitroimidazoles |
|Nitroimidazoles |
||
Line 148: | Line 162: | ||
| |
| |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| |
| |
||
|- |
|- |
||
Line 154: | Line 168: | ||
|[[tetracyclines]] |
|[[tetracyclines]] |
||
| |
| |
||
| style="text-align:center" | |
| style="text-align:center" |– |
||
| |
| |
||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
Line 176: | Line 190: | ||
| style="text-align:center" | + |
| style="text-align:center" | + |
||
|} |
|} |
||
* † if inflammation present |
|||
[[Category:Antimicrobials]] |
[[Category:Antimicrobials]] |
Revision as of 16:23, 24 August 2020
Class | Antimicrobial | Blood | CNS | Urine | Prostate | Necrotic |
---|---|---|---|---|---|---|
Antibiotics: β-Lactams | ||||||
Penicillins | β-lactamase inhibitors | – | ||||
ampicillin | + | – | ||||
piperacillin-tazobactam | +† | |||||
Cephalosporins | first-generation cephalosporins | – | – | |||
second-generation cephalosporins | – | |||||
third-generation cephalosporins | +† | |||||
cefepime | + | |||||
ceftazidime | + | + | ||||
Cephamycins | cephamycins | – | ||||
cefoxitin | – | |||||
Carbapenems | imipenem | + | ||||
Antibiotics: Non-β-Lactams | ||||||
Aminoglycosides | – | |||||
Chloramphenicol | chloramphenicol | + | ||||
Fluoroquinolones | –? | + | + | |||
Lincosamides | clindamycin | – | + | |||
Macrolides | macrolides | – | + | |||
Nitrofurans | nitrofurantoin | – | – | + | – | – |
Nitroimidazoles | metronidazole | + | ||||
Rifamycins | rifampin | + | ||||
Sulfonamides | sulfamethoxazole | – | ||||
Tetracyclines | tetracyclines | – | + | |||
doxycycline | + | |||||
Antifungals | ||||||
Azoles | fluconazole | + |
- † if inflammation present
References
- ^ Tomasz Jodlowski, Charles R Ashby, Sarath G Nath. Doxycycline for ESBL-E Cystitis. Clinical Infectious Diseases. 2020. doi:10.1093/cid/ciaa1898.
- a b c d e f g h i Timothy Felton, Peter F. Troke, William W. Hope. Tissue Penetration of Antifungal Agents. Clinical Microbiology Reviews. 2014;27(1):68-88. doi:10.1128/cmr.00046-13.
- ^ nau2010pe
- ^ Cornelia B. Landersdorfer, Jürgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz Sörgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.
- a b c d e f g h i j k l m n o p q r L. Brockhaus, D. Goldblum, L. Eggenschwiler, S. Zimmerli, C. Marzolini. Revisiting systemic treatment of bacterial endophthalmitis: a review of intravitreal penetration of systemic antibiotics. Clinical Microbiology and Infection. 2019;25(11):1364-1369. doi:10.1016/j.cmi.2019.01.017.
- a b Takashi Suzuki, Toshihiko Uno, Guangming Chen, Yuichi Ohashi. Ocular distribution of intravenously administered micafungin in rabbits. Journal of Infection and Chemotherapy. 2008;14(3):204-207. doi:10.1007/s10156-008-0612-5.
- ^ Tony H. Huynh, Mark W. Johnson, Grant M. Comer, Douglas N. Fish. Vitreous Penetration of Orally Administered Valacyclovir. American Journal of Ophthalmology. 2008;145(4):682-686. doi:10.1016/j.ajo.2007.11.016.
- ^ Luis F. López-Cortés, R. Ruiz-Valderas, M. J. Lucero-Muñoz, E. Cordero, M. T. Pastor-Ramos, J. Marquez. Intravitreal, Retinal, and Central Nervous System Foscarnet Concentrations after Rapid Intravenous Administration to Rabbits. Antimicrobial Agents and Chemotherapy. 2000;44(3):756-759. doi:10.1128/aac.44.3.756-759.2000.